Gene · 2767
Papers2,923
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,923
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Direct interrogation of context-dependent GPCR activity with a universal biosensor platform. | bioRxiv | 2024 | 38260348 | PubTator, text mining | PubMed |
| Calcium Electroporation versus Electrochemotherapy with Bleomycin in an In Vivo CAM-Based Uveal Melanoma Xenograft Model. | Int J Mol Sci | 2024 | 38256012 | PubTator, text mining | PubMed |
| Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis. | Acta Neuropathol Commun | 2024 | 38254245 | PubTator, text mining | PubMed |
| Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma. | Clin Cancer Res | 2024 | 38252427 | PubTator, text mining | PubMed |
| Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature. | Dermatopathology (Basel) | 2024 | 38247727 | PubTator, text mining | PubMed |
| Piecing together the mosaic of rare skin diseases: an interview with Veronica Kinsler. | Dis Model Mech | 2024 | 38235593 | PubTator, text mining | PubMed |
| Cooperative function of oncogenic MAPK signaling and the loss of Pten for melanoma migration through the formation of lamellipodia. | Sci Rep | 2024 | 38233537 | PubTator, text mining | PubMed |
| INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas. | Nat Cancer | 2024 | 38233483 | PubTator, text mining | PubMed |
| Clinical and outcome comparison of genetically positive vs. negative patients in a large cohort of suspected familial hypocalciuric hypercalcemia. | Endocrine | 2024 | 38214877 | PubTator, text mining | PubMed |
| Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma. | J Med Chem | 2024 | 38198520 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation in ophthalmic diseases: From mechanisms to potential applications. | Heliyon | 2024 | 38192819 | PubTator, text mining | PubMed |
| Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease. | J Exp Clin Cancer Res | 2024 | 38191418 | PubTator, text mining | PubMed |
| Expression of GNAQ, BAP1, SF3B1, and EIF1AX Proteins in the Aqueous Humor of Eyes Affected by Uveal Melanoma. | Invest Ophthalmol Vis Sci | 2024 | 38175637 | PubTator, text mining | PubMed |
Transcriptional profiling of human peripheral blood mononuclear cells in household contacts of pulmonary tuberculosis patients provides insights into mechanisms of Mycobacterium tuberculosis control and elimination. | Emerg Microbes Infect | 2024 | 38088554 | PubTator, text mining | PubMed |
| Functional profiling of the G protein-coupled receptor C3aR1 reveals ligand-mediated biased agonism. | J Biol Chem | 2024 | 38072064 | PubTator, text mining | PubMed |
| Design, synthesis and evaluation of quinazoline derivatives as Gαq/11 proteins inhibitors against uveal melanoma. | Bioorg Chem | 2024 | 38043397 | PubTator, text mining | PubMed |
| Characterization of Patient-Derived GNAQ Mutated Endothelial Cells from Capillary Malformations. | J Invest Dermatol | 2024 | 38013159 | PubTator, text mining | PubMed |
| Anastomosing haemangioma of the mediastinum: Clinicopathological series with radiological and genetic characterisation. | Histopathology | 2024 | 37936489 | PubTator, text mining | PubMed |
| GNAQ/GNA11 Mosaicism Is Associated with Abnormal Serum Calcium Indices and Microvascular Neurocalcification. | J Invest Dermatol | 2024 | 37802294 | PubTator, text mining | PubMed |
| GNAQ/GNA11 Mosaicism Causes Aberrant Calcium Signaling Susceptible to Targeted Therapeutics. | J Invest Dermatol | 2024 | 37802293 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2767/papers?page=10